BioMedTech Press Release

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck

“We are very proud that, after a highly competitive selection process, Merck has chosen Diaccurate to bring DIACC3010 into advanced clinical development”, said Dominique Bridon, Ph.D., CEO of Diaccurate.

  • DIACC3010, formerly M2698, is a Phase II-ready dual PAM inhibitor with rare brain-penetration properties

  • Merck to become a shareholder of Diaccurate, remains fully committed to the success of the drug candidate

  • Diaccurate to start exploratory Phase II programs in incurable solid tumors and lymphomas by H2 2022

  • Acquisition broadens Diaccurate’s sole-in-class oncology and immunotherapy product pipeline and transforms it into a clinical−stage biotech mpany